Skip to main content
Back
OTSKF logo

Otsuka Holdings Co., Ltd.

Data quality: 100%
Overbought
OTSKF
OTC Healthcare Drug Manufacturers - General
$69.59
▼ $0.75 (-1.07%)
Mkt Cap: 36.75B
Also listed as OTSKY OTC
Day Range
$69.59 $69.59
52-Week Range
$44.40 $70.34
Volume
212
50D / 200D Avg
$57.93 / $52.15
Prev Close
$70.34

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 12.6 3.8
Net Margin % 14.7 3.9
Rev Growth 5Y % 13.3 10.0
D/E 0.1 0.2

Key Takeaways

Revenue grew 13.32% annually over 5 years — strong growth
ROE of 12.60% — decent returns on equity
Debt/Equity of 0.10 — conservative balance sheet
Generating 316.01B in free cash flow
P/E of 0.10 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.26%

Growth

Revenue Growth (5Y)
13.32%
Revenue (1Y)6.06%
Earnings (1Y)5.93%
FCF Growth (3Y)36.92%

Quality

Return on Equity
12.60%
ROIC9.26%
Net Margin14.71%
Op. Margin16.71%

Safety

Debt / Equity
0.10
Current Ratio2.17
Interest Coverage15.26

Valuation

P/E Ratio
0.10
P/B Ratio0.01
EV/EBITDA-0.46
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6.06% Revenue Growth (3Y) 10.64%
Earnings Growth (1Y) 5.93% Earnings Growth (3Y) 72.88%
Revenue Growth (5Y) 13.32% Earnings Growth (5Y) 30.46%
Profitability
Revenue (TTM) 2.47T Net Income (TTM) 363.47B
ROE 12.60% ROA 8.65%
Gross Margin 71.68% Operating Margin 16.71%
Net Margin 14.71% Free Cash Flow (TTM) 316.01B
ROIC 9.26% FCF Growth (3Y) 36.92%
Safety
Debt / Equity 0.10 Current Ratio 2.17
Interest Coverage 15.26 Dividend Yield 0.02%
Valuation
P/E Ratio 0.10 P/B Ratio 0.01
P/S Ratio 0.01 PEG Ratio 1.52
EV/EBITDA -0.46 Dividend Yield 0.02%
Market Cap 36.75B Enterprise Value -191.05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.47T 2.33T 2.02T 1.74T 1.50T
Net Income 363.47B 343.12B 121.62B 133.91B 125.46B
EPS (Diluted) 685.44 633.77 224.10 246.79 231.15
Gross Profit 1.77T 1.67T 1.41T 1.17T 1.00T
Operating Income 412.79B 323.56B 139.61B 150.32B 154.50B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 4.20T 3.74T 3.36T 3.10T 2.82T
Total Liabilities 1.10T 961.09B 924.93B 840.17B 775.73B
Shareholders' Equity 3.04T 2.73T 2.39T 2.23T 2.01T
Total Debt 307.31B 189.38B 214.19B 194.16B 212.45B
Cash & Equivalents 535.11B 426.17B 513.34B 471.63B 410.68B
Current Assets 1.62T 1.37T 1.33T 1.19T 1.05T
Current Liabilities 749.77B 632.66B 667.23B 539.19B 467.91B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#525 of 1024
45
Custom Deep Value Investing (Seth Klarman)
#334 of 820
47
Growth Price/Sales Ratio Focus (Ken Fisher)
#586 of 616
6
Value Defensive Investing (Benjamin Graham)
#530 of 708
15

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026